Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plus Therapeutics, Inc. (NASDAQ: PSTV) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering investors a structured view of its financial condition, capital structure, governance, and clinical-stage operations. As a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and CNS cancer diagnostics, Plus Therapeutics uses SEC reports to describe its business, risks, and material events.
Core filings such as the Form 10-K annual report and Form 10-Q quarterly reports provide detailed discussions of the company’s radiotherapeutic pipeline, including REYOBIQ™ (rhenium Re186 obisbemeda), its CNSide Diagnostics subsidiary, grant funding, and liquidity. These documents also outline risk factors related to clinical development, regulatory approvals, Nasdaq listing standards, and capital needs.
Frequent Form 8-K current reports disclose material events, including Nasdaq notices about minimum bid price and stockholders’ equity compliance, extensions to regain listing compliance, purchase agreements with institutional investors, public offerings of common stock and warrants, and significant lease or financing arrangements. Proxy materials on Schedule 14A describe board elections, stock incentive plans, reverse stock split authority, and stockholder voting outcomes.
On this page, Stock Titan enhances access to these filings with AI-powered summaries that explain key points in plain language, helping users quickly understand complex documents such as registration statements on Form S-1, equity purchase agreements, or governance-related filings. Real-time integration with the SEC’s EDGAR system ensures new Plus Therapeutics filings appear promptly.
Investors can also use this section to monitor potential insider activity reported on ownership forms, as well as to follow any future proxy statements addressing compensation or capital structure changes. By combining raw filings with AI-generated highlights, the page is designed to make Plus Therapeutics’ regulatory history and ongoing disclosure record more accessible to both experienced and newer market participants.
Plus Therapeutics updated its executive pay disclosure by adding 2025 discretionary cash bonuses for its named executive officers. The Compensation Committee approved these bonuses on February 9, 2026, completing the previously incomplete 2025–2024 summary compensation table originally referenced in a Form S-1 registration statement.
For 2025, President and CEO Marc H. Hedrick, M.D. received total compensation of $5,566,732, including a $585,000 salary, option awards valued at $3,531,841, restricted stock awards of $1,100,647, non-equity incentive plan compensation of $305,663, and other compensation of $43,581. Chief Financial Officer Andrew Sims received 2025 total compensation of $1,631,279, including a $390,000 salary, option awards of $810,388, restricted stock awards of $264,154, non-equity incentive plan compensation of $149,175, and other compensation of $17,562. Former Chief Medical Officer Norman LaFrance, M.D., who stepped down on June 11, 2024, shows no 2025 compensation, with 2024 total compensation of $285,912.
CVI Investments, Inc. and Heights Capital Management, Inc. filed a Schedule 13G reporting beneficial ownership of 12,368,423 shares of Plus Therapeutics, Inc. common stock, representing 6.9% of the outstanding shares. All reported shares are held with shared voting and shared dispositive power, with no sole voting or dispositive authority. Heights Capital Management acts as investment manager to CVI Investments and may be deemed a beneficial owner, but both parties disclaim beneficial ownership beyond their pecuniary interest. The ownership percentage is based on 178,371,232 shares outstanding as indicated in a Plus Therapeutics prospectus filed on January 14, 2026. The filers certify that the securities are held without the purpose or effect of changing or influencing control of Plus Therapeutics.
Plus Therapeutics, Inc. filed a current report noting that it has updated its corporate investor presentation for use in meetings with investors, analysts, and other stakeholders. The updated materials are provided as an exhibit labeled an investor presentation as of January 22, 2026.
The company indicates that these slides are intended to support discussions about its business with the financial community and others by providing a refreshed overview in a single document.
Plus Therapeutics, Inc. completed an underwritten public offering of 39,473,684 shares of common stock and 39,473,684 warrants at a combined public offering price of $0.38 per share and warrant, generating approximately $13.3 million in net proceeds after underwriting discounts, commissions and expenses. The company also granted the underwriter a 30-day option to buy up to an additional 5,921,052 shares, additional warrants to purchase up to 5,921,052 shares, or a combination, and the underwriter exercised this option for additional warrants to purchase 5,921,052 shares. Each warrant is immediately exercisable at $0.38 per share and expires five years from issuance, and the company expects to use the net proceeds for working capital and general corporate purposes. The company and its directors and executive officers agreed to 45-day lock-up restrictions, and the company agreed to avoid variable rate transactions for 120 days after the final prospectus date.
Plus Therapeutics, Inc. has filed an S-1 to offer 22,321,429 units and 22,321,429 pre-funded units, each tied to one share (or pre-funded warrant) and one warrant, in an underwritten transaction. The assumed public offering price is $0.56 per unit, based on the January 6, 2026 Nasdaq closing price of the common stock, and each warrant is expected to have a $0.56 exercise price and a five-year term. The company is also registering the shares of common stock underlying the warrants and pre-funded warrants and has granted the underwriter an over-allotment option for up to 3,348,214 additional shares, pre-funded warrants and/or warrants. As of January 2, 2026, 138,897,548 shares of common stock were outstanding. The company highlights substantial net losses, going-concern doubt, dependence on additional financing, and the risk of Nasdaq delisting, alongside significant potential dilution and limited liquidity for the non-listed pre-funded warrants and warrants.
Plus Therapeutics, Inc. (PSTV) announced that Nasdaq has granted the company an additional 180-day period, until May 11, 2026, to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The prior deadline had been November 12, 2025, after the stock traded below $1.00 for 30 consecutive business days as of May 16, 2025.
The company plans to continue monitoring its share price and has confirmed to Nasdaq that, if necessary, it will implement a reverse stock split of its common stock to attempt to restore compliance. If compliance is not regained within the extended period, Nasdaq may commence delisting of the common stock, which the company would have the right to appeal. There is no assurance that Plus Therapeutics will regain or maintain compliance with Nasdaq listing standards.
Plus Therapeutics (PSTV) reported an insider purchase by its Chief Financial Officer. On 11/04/2025, the CFO acquired 20,000 shares of common stock at a weighted average price of $0.51, with individual trades executed between $0.504 and $0.509. Following the transaction, the reporting person beneficially owns 68,138 shares, held directly.
The filing notes the purchase details were made across multiple trades, and the reporting person will provide a breakdown of shares bought at each price within the stated range upon request.
Plus Therapeutics (PSTV) filed its Q3 2025 10‑Q showing wider year‑to‑date losses but a stronger balance sheet from recent financings. The company reported a Q3 net loss of
Liquidity improved: cash and cash equivalents were
The filing states substantial doubt about continuing as a going concern due to ongoing losses and funding needs. Nasdaq confirmed compliance with equity standards, but PSTV remains out of compliance with the $1.00 minimum bid price requirement, with a grace period through November 12, 2025. Shares outstanding were 137,429,055 as of October 29, 2025.
Plus Therapeutics (PSTV) filed an 8-K stating it reported financial results for the third quarter ended September 30, 2025. The company furnished a press release with details as Exhibit 99.1, which is incorporated by reference.
The disclosure under Item 2.02 is furnished, not filed, under the Exchange Act. This routine update provides access to the company’s Q3 2025 results through the attached press release.